BAVIS_1170x120_1-20

Coronavirus will slow down global drug development, says new survey

Print Friendly, PDF & Email
CAMBRIDGE, Mass. — New drugs need to be tested in clinical trials to be approved. However, a recent survey from Clinical Research IO shows that investigators conducting clinical trials on a wide range of diseases are experiencing significant interruptions in their trials due to the ongoing coronavirus crisis.

24% of investigators reported that they have stopped enrolling new patients due to patient safety concerns, and of the 76% remaining investigators, nearly half, or 37%, indicated they are considering halting new patient enrollment.

“We noticed a significant slowdown in patient recruitment in the beginning of March,” said Dr. Elena Christofides, owner and principal investigator of Endocrinology Associates. “We then decided that it was in the best interest of public safety to halt all further enrollment.”

This slowdown has been further exacerbated by the recent spate of shelter-in-place orders imposed by states and municipalities. “Due to COVID-19 restrictions in health care, clinical trial activity has largely come to a halt,” said Dr. Marcus Stone, CEO of The Spine Institute of Louisiana Foundation.

“This will lead to a significant slowdown in new drug and device development,” said Dr. Stone. “New treatments that could have come out in, say, 2022 now might come out in 2023. So, this COVID-19 crisis could have a significant long-term effect on health care in general.”

Even for sites that are continuing to enroll, significant challenges remain. The survey indicated that sites are reporting a 9% decrease in patient retention – meaning nearly one in ten enrolled subjects may be withdrawing from their studies. Furthermore, 63% are reporting that they have prohibited on-site monitoring by pharmaceutical sponsors and their agents, thus inhibiting the ability of sponsors to perform effective oversight.

“This is one of the second-order casualties of the covid crisis,” said Raymond Nomizu, CEO of Clinical Research IO, the clinical trials software vendor that administered the survey. “When we look back five years from now, I fully expect to see a drop in the number of breakthrough new medications being approved – a drop you can directly tie to this crisis.”

The survey was conducted March 19-23, 2020. In total, 73 research sites across a range of therapeutic indications participated.


NT_728x90_10-3-18

TRP_728x90_12-19-19

Comments are closed.